Research programme: siRNA delivery therapeutics - siRNAx
Latest Information Update: 11 Aug 2016
At a glance
- Originator siRNAx
- Class Recombinant fusion proteins; RNA
- Mechanism of Action RNA interference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Waldenstrom's macroglobulinaemia
Most Recent Events
- 11 Aug 2016 Early research in Waldenstrom's macroglobulinaemia in USA (Parenteral)